Immunovant

IMVT

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding

In their latest 13F (Q3 2026)

See who

Value held

$3.6m

Combined value at quarter end

Last quarter

0 bought

0 sold or trimmed

Price at Q2 ’26 end

$38.53

+55.1% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

+55.1%Q2 ’26

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

0Q4 ’23

0Q1 ’24

0Q2 ’24

0Q3 ’24

0Q4 ’24

0Q1 ’25

0Q2 ’25

0Q3 ’25

0Q4 ’25

1Q1 ’26

1Q2 ’26

0Q3 ’26

Counts the managers on this site whose 13F for that quarter includes Immunovant.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Immunovant

Greenlight Capital	0.1%$3.6m	$3.6m	Unchanged	2 qtrs

Download the holders: CSV · JSON · Markdown

About the company

Sector: Health care · Biological Products, (No Diagnostic Substances)
Incorporated in: Delaware
Financial year ends: 31 March
Shares outstanding: 207m at 3 Aug 2026
SEC filings: Annual reports and other filings on EDGAR

Revenue and profit

Immunovant revenue and net income by year
Year	Revenue	Net income
Year to Mar 2026	–	−$506m
Year to Mar 2025	–	−$414m
Year to Mar 2024	–	−$259m
Year to Mar 2023	–	−$211m
Year to Mar 2022	–	−$157m
Year to Mar 2021	–	−$107m

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.